Illumina (ILMN) Issues FY19 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.50-6.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.44. The company issued revenue guidance of +13-14% to $3.76-3.80 billion, compared to the consensus revenue estimate of $3.79 billion.Illumina also updated its FY 2019 guidance to $6.50-6.60 EPS.

Shares of NASDAQ ILMN opened at $293.52 on Thursday. Illumina has a one year low of $216.34 and a one year high of $372.61. The firm has a market capitalization of $43.44 billion, a P/E ratio of 51.31, a P/E/G ratio of 2.03 and a beta of 1.20. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million for the quarter, compared to analyst estimates of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.44 EPS. Equities research analysts expect that Illumina will post 6.51 earnings per share for the current year.

ILMN has been the topic of a number of recent research reports. BidaskClub upgraded shares of Illumina from a sell rating to a hold rating in a research note on Wednesday. Zacks Investment Research lowered shares of Illumina from a buy rating to a hold rating in a research note on Wednesday, October 24th. UBS Group upgraded shares of Illumina from a neutral rating to a buy rating and upped their target price for the stock from $340.00 to $370.00 in a research note on Thursday, January 3rd. Barclays increased their price target on shares of Illumina from $350.00 to $370.00 and gave the company an overweight rating in a research note on Wednesday, October 24th. Finally, Leerink Swann upgraded shares of Illumina to an outperform rating and dropped their price target for the company from $380.00 to $365.00 in a research note on Wednesday, January 30th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of $346.40.

In related news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction on Wednesday, December 26th. The stock was sold at an average price of $273.87, for a total transaction of $903,771.00. Following the completion of the sale, the director now directly owns 339,879 shares of the company’s stock, valued at $93,082,661.73. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,345 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $343.57, for a total value of $462,101.65. Following the sale, the director now directly owns 6,101 shares of the company’s stock, valued at $2,096,120.57. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,947 shares of company stock worth $11,026,616. Insiders own 0.54% of the company’s stock.

WARNING: This piece was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/02/14/illumina-ilmn-issues-fy19-earnings-guidance.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

See Also: Why is cost of goods sold important?

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply